BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17875936)

  • 1. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.
    Falsetti SC; Wang DA; Peng H; Carrico D; Cox AD; Der CJ; Hamilton AD; Sebti SM
    Mol Cell Biol; 2007 Nov; 27(22):8003-14. PubMed ID: 17875936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.
    Hamada M; Miki T; Iwai S; Shimizu H; Yura Y
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):559-69. PubMed ID: 21107573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.
    Dan HC; Jiang K; Coppola D; Hamilton A; Nicosia SV; Sebti SM; Cheng JQ
    Oncogene; 2004 Jan; 23(3):706-15. PubMed ID: 14737105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
    Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
    Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.
    Chan LN; Fiji HD; Watanabe M; Kwon O; Tamanoi F
    PLoS One; 2011; 6(10):e26135. PubMed ID: 22028818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
    Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.
    Gentry LR; Nishimura A; Cox AD; Martin TD; Tsygankov D; Nishida M; Elston TC; Der CJ
    J Biol Chem; 2015 Sep; 290(37):22851-61. PubMed ID: 26216878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
    Tecleab A; Zhang X; Sebti SM
    J Biol Chem; 2014 Nov; 289(45):31296-309. PubMed ID: 25210032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RalA and RalB proteins are ubiquitinated GTPases, and ubiquitinated RalA increases lipid raft exposure at the plasma membrane.
    Neyraud V; Aushev VN; Hatzoglou A; Meunier B; Cascone I; Camonis J
    J Biol Chem; 2012 Aug; 287(35):29397-405. PubMed ID: 22700969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis.
    Wang H; Owens C; Chandra N; Conaway MR; Brautigan DL; Theodorescu D
    Cancer Res; 2010 Nov; 70(21):8760-9. PubMed ID: 20940393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival.
    Chien Y; White MA
    EMBO Rep; 2003 Aug; 4(8):800-6. PubMed ID: 12856001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
    Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
    Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential involvement of RalA and RalB in colorectal cancer.
    Martin TD; Der CJ
    Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling.
    Balasubramanian N; Meier JA; Scott DW; Norambuena A; White MA; Schwartz MA
    Curr Biol; 2010 Jan; 20(1):75-9. PubMed ID: 20005108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and involvement of Ral GTPases in colorectal cancer.
    Martin TD; Samuel JC; Routh ED; Der CJ; Yeh JJ
    Cancer Res; 2011 Jan; 71(1):206-15. PubMed ID: 21199803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
    Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
    J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.